accountsaid Edouard Aubery, an analyst at Equinet AG in Frankfurt. ���This is a very promising small molecule with blockbuster potential,��� Aubery said in an interview. ���This is a relatively cheap drug compared to the biologics like Enbrel.��� Vidofludimus...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Arthritis Drug���s $1.4 Billion Promise for 4SC Hinges on Study
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account